Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-414 placebo-controlled randomized study in healthy adults and elderly participants
jRCT2071200106Completed
- Sponsor
- KM Biologics
- Start
- Mar 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing KD-414 vaccine with Placebo (2 arms). Primary endpoints: Neutralizing antibody seroconversion rate against SARS-CoV-2 at 28 days after the second dose, Adverse events through 28 days after second dose and 5 more. Started Mar 2021; status: completed.
02
Drugs
KD-414
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071200106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200106.